

#62  
MB  
07/12/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

VAN NEST et al.

Serial No.: 08/418,870

Group Art Unit: 1643

Filing Date: April 7, 1995

Examiner: D. Wortman

Title: ADJUVANT FORMULATION COMPRISING SUBMICRON  
OIL DROPLET EMULSION

RECEIVED  
TECH CENTER 1300/2300  
00 JUN 27 PM 10:45

DECLARATION OF GARY OTT, Ph.D.

Assistant Commissioner for Patents  
Washington, D.C. 20231

I, Gary Ott, hereby declare as follows:

1. I am currently employed by Chiron Corporation, 4560 Horton Street, Emeryville, California, where I have worked since 1986. I am currently a Senior Scientist in Vaccine Research. During my employment with Chiron Corporation, I have investigated the mechanism of action of emulsion adjuvants for vaccination, developed various adjuvant formulations, as well as synthesis and analytical assay techniques. I have worked extensively on the development of the MF59<sup>TM</sup> adjuvant, a commercial embodiment of a representative submicron oil-in-water emulsion as claimed in the above-identified application. This work included laboratory synthesis, assay development, production and analysis for clinical materials.

2. I received a B.A. in Chemistry, Magna cum Laude and a B.S. in Biological Sciences in 1969 from the University of California, Irvine. I received a Ph.D. in Biochemistry from the

University of Colorado in 1974. I have coauthored 33 papers relating to various topics including adjuvant technology. A copy of my *curriculum vitae* is attached hereto as Exhibit A.

3. I am a coninventor of the above-identified patent application, U.S. Serial No. 08/418,870 ("the application"), and have read the Office Action dated January 31, 2000 ("Office Action"). I have also reviewed and am familiar with Woodard et al., *Vaccine* 3:137-145 (1985) ("Woodard"), and Silvestri et al., *International Journal of Pharmaceutics*, 50:141-146 (1989) ("Silvestri"), cited against the pending claims in the Office Action. In particular, the Office Action states that both of these references "deal with the desirability of making stable oil-in-water emulsions and teach how to vary the relevant parameters to achieve stability; one of the relevant parameters is droplet size." Office Action, page 3. However, I do not believe the invention is suggested by this combination of references. My opinion is based on the facts set forth below, as well as my familiarity with the subject matter.

4. In particular, the pending claims pertain to an adjuvant composition and methods of using the composition. The adjuvant composition consists essentially of a metabolizable oil, present in an amount of 0.5% to 20% of the total volume, and an emulsifying agent, present in an amount of 0.01% to 2.5% by weight (w/w). The oil and emulsifying agent are in the form of a submicron oil-in-water emulsion (i.e., an emulsion having oil droplets substantially all of which are about 100 nm to about 750 nm in diameter). The adjuvant composition is capable of increasing the immune response to an antigen when administered with the antigen.

5. As discussed with the Examiner in the interview of April 20, 2000, Woodard and Silvestri suggest fundamentally different emulsions than those emulsions claimed in the present application, both in physical constituents and in their mechanism of action. In particular, Woodard points out at page 139, Table 2, that stability is achieved with emulsifier concentrations of 4% or higher. The present composition, on the other hand, utilizes emulsifier concentrations of 0.01% to 2.5% by weight. Table 2 of Woodard suggests that when emulsifying agents are present at such low concentrations, heavy creaming (and hence lack of stability) occurs. Moreover, as explained in the interview and as illustrated in the attached Figures 1A and 1B, Woodard teaches that an antigen must be added to the internal phase (i.e., the oil phase in oil-in-water emulsions and the aqueous phase in water-in-oil emulsions), for optimal antibody

response; and that addition of the antigen to the external (continuous) phase reduces antibody production considerably (see Woodard, page 142, right column, 2<sup>nd</sup> paragraph). In order to “force” the antigen into the internal phase, the antigen is mixed with Woodard’s oil and emulsifying agent prior to emulsification (mixing of the phases) which produces the submicron oil-in-water emulsion. See, e.g., page 139, right column, 3<sup>rd</sup> full paragraph. Thus, Woodard’s submicron oil-in-water emulsion does not exist in the absence of antigen.


6. As discussed with the Examiner in the interview, Woodard formulates his adjuvant composition in this manner because the compositions are delivery systems designed to transport an antigen or another particle within the oil phase to antigen presenting cells (APCs). Thus, Woodard’s compositions are used as vehicles for adjuvants. In contrast, the claimed adjuvant compositions, while capable of increasing the immune response to an antigen when administered with the antigen, does not contain an antigen. The claimed adjuvant compositions appear to work by direct stimulation or short term recruitment of APCs to the injection site.

7. Additionally, although Silvestri discloses that the stability of emulsions is improved by submicron size droplets, the reference does not pertain to adjuvants. Rather, the reference reiterates Woodard’s teaching that the submicron emulsions are used as drug delivery systems to deliver drugs via the internal phase of the emulsion (see page 142, left column). As explained above, the emulsions in the claimed composition are not merely delivery systems, they act as adjuvants themselves.

8. Based on the foregoing, it is my opinion that the claimed compositions and methods of use are distinct from the emulsions disclosed in the cited references.

9. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date 6/13/00

x   
\_\_\_\_\_  
Gary Ott, Ph.D.

**EXHIBIT A**

## *Curriculum Vitae*

Name: Gary Ott

Date of Birth: May 18, 1947

Place of Birth: Long Beach, CA

Education: B.A. 1969 Chemistry Magna cum Laude  
B.S. 1969 Biological Sciences  
University of California, Irvine

Ph.D. 1974 Biochemistry  
University of Colorado

Research and Professional Positions: 1969/1974 Research Associate  
Laboratory of Dr. William Bauer  
Dept. of Chemistry  
University of Colorado  
Boulder, CO

1974/1978 Postdoctoral Fellow  
Laboratory of Dr. Walter Sauerbier  
Dept. of Genetics and Biophysics  
University of Colorado  
Health Sciences Center  
Denver, CO

1978/1979 Automobile Mechanic  
Capitol Motors  
Denver, CO

1979/1981 Postdoctoral Fellow  
Laboratory of Dr. Virgie Shore  
Biomedical Science Division  
Lawrence Livermore Laboratory  
Livermore, CA

1981/1986 Scientist/Senior Scientist  
BioRad Laboratories  
Richmond, CA

1986/present Scientist/Senior Scientist  
Vaccine Research  
Chiron Corporation  
Emeryville, CA

Honors and Professional Societies: Outstanding Undergraduate Chemist Award, UC Irvine – 1969  
NDEA Predoctoral Fellow, University of Colorado – 1969-1972  
PHI Lambda Upsilon Honor Society, University of Colorado – 1970-1974

Professional interests: 1994/present Research into the mechanism of action of emulsion  
adjuvants for vaccination. Development of  
biodegradable polymer adjuvant formulations  
(Synthesis and analytical assay development)

1990/1994	Development of the MF59 emulsion adjuvant for human vaccination (laboratory synthesis and assay development, scale-up and GMP production and analysis for clinical materials)
1986/1990	Purification of viral glycoprotein antigens for human vaccination (laboratory purification and analysis, scale-up and GMP production and analysis of clinical materials).
1981/1986	Development of materials for separation of biological macromolecules (laboratory development and analysis, transfer to manufacturing, QC development)

Papers:

1. Ott, G., Ziegler, R., and Bauer, W.R. The DNA Melting Transition in Aqueous Magnesium Salt Solutions. *Biochemistry* 14:3431, 1975.
2. Carlson, J., Ott, G., and Sauerbier, W. Transcriptional Organization of the Drosophila Melanogaster Ribosomal Genes. *J. Mol. Biol.* 112:353, 1977.
3. Ott, G., Bastia, D., and Bauer, W.R. A Spectroscopic and Electron Microscopic Examination of the Highly Condensed DNA Structure Formed by Denaturation in  $\text{McClO}_4$ . *Biochimica et Biophysica Acta.* 518:216, 1978.
4. Giorno, R., Ott, G., and Sauerbier, W. Size Analysis of Heterogeneous Nuclear RNA in Aqueous Gel System. *Biochimica et Biophysica Acta.* 521:235, 1978.
5. Ott, G., and Shore, V. Anion-exchange High Performance Liquid Chromatography of Human Serum Apolipoproteins. *J. Chrom. Biomed. Ap.* 231:1, 1982.
6. Wehr, C.T., Cunico, R.L., Ott, G.S., and Shore, V.G. Preparative Size Exclusion Chromatography of Human Serum Apolipoproteins Using an Analytical Liquid Chromatograph. *Anal. Biochem.* 125:386, 1982.
7. Ott, G.S. and Shore, V.G. Analytical and Preparative Separations of Plasma Apolipoproteins. *Handbook of Electrophoresis Vol. III*, Lewis, L. ed. CRC Press Inc., Boca Raton, FL, 1983.
8. Juarez-Salinas, H., Ott, G.S., Stanker, L.H., Brooks, T.L., and Chen, J.-C. Separation of IgG Idiotypes by High Performance Hydroxyapatite Chromatography, *Methods in Enzymology*, 121:615, 1986.
9. Burke, D.J., Duncan, J.K., Dunn, L.C., Cummings, L., Siebert, C.J., and Ott, G.S. Rapid Anion-Exchange Chromatography of Proteins. *J. Chromat.* 353:425, 1985.
10. Burke, D.J., Duncan, J.K., Siebert, C.J., and Ott, G.S. Rapid Cation-Exchange Chromatography of Hemoglobins and Other Proteins. *J. Chromat.* 359:533, 1985.
11. Sanchez-Pescador, L., Burke, R.L., Ott, G., and Van Nest, G. The Effect of Adjuvants on the Efficacy of a Recombinant HSV Glycoprotein Vaccine. *J. Immunol.* 141:1720, 1988.

12. Sanchez-Pescador, L., Burke, R., Ott, G., Larsen, C., Gervase, B., and Van Nest, G. Comparison of Adjuvant Efficacy for a Recombinant Herpes Simplex Glycoprotein Vaccine. In *Technological Advances in Vaccine Development*, Lasky, L. and Fox, C.F. eds. Academic Press, New York, 84:455-469, 1988.
13. Burke, R., Van Nest, G., Carlson, J., Gervase, B., Goldbeck, C., Ng, P., Sanchez-Pescador, L., Stanberry, L., and Ott, G. Development of a Herpes Simplex Virus Subunit Vaccine. In *Vaccines 89: Modern Approaches to New Vaccines including Prevention of AIDS*, Lerner, R., Ginsberg, H., Channock, R., and Brown, F. eds., Cold Spring Harbor, NY, 377, 1989.
14. Stanberry, L.R., Harrison, C.J., Bernstein, D.I., Burke, R.L., Shulka, R., Ott, G., and Myers, M.G. Factors Influencing Herpes Simplex Glycoprotein Immunotherapy of Recurrent Disease. *Antiviral Res.* 11:203, 1989.
15. Haigwood, N., Nara, P., Brooks, E., Van Nest, G., Ott, G., Higgins, K., Dunlop, N., Scandella, C., Eichborg, J., and Steimer, K. Native but not Denatured HIV-1 gp120 Generates Broad Spectrum Neutralizing Antibody in Baboons. *J. Virol.* 1:172, 1992.
16. Ott, G., Van Nest, G., and Burke, R. The Use of Muramyl Peptides as Vaccine Adjuvants. In *Vaccine Research and Developments*, Koff, W. and Six, H. eds., Dekker, New York, 89, 1992.
17. Van Nest, G., Steimer, K., Haigwood, N., Burke, R., and Ott, G. Advanced Adjuvant Formulations for Use with Recombinant Subunit Vaccines. In *Vaccines 92*, Cold Spring Harbor Press, Cold Spring Harbor, New York, 57, 1992.
18. Burke, R., Goldbeck, C., Ng, P., Stanberry, L., Ott, G., and Van Nest, G. The Role of Adjuvant in an Immunotherapeutic Vaccine Formulation for Treatment of Genital Herpes, *J. Inf. Dis.* 170:1110, 1994.
19. Ott, G., Barchfeld, G.L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., and Van Nest, G. MF59: Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines. In *Vaccine Design: The Subunit Approach*, Powell, M. and Newman, M. eds., Plenum Publishing, New York, 277, 1995.
20. Ott, G., Barchfeld, G., and Van Nest, G. Enhancement of Humoral Response Against Human Influenza Vaccine with the Simple Submicron Oil/Water Emulsion MF59. *Vaccine* 13:1557, 1995.
21. O'Hagan, D.T., Ott, G.S., and Van Nest, G. Recent Advances in Vaccine Adjuvants: The Development of the MF59 Emulsion and Polymeric Microparticles. *Mol. Med. Today*, 3:69, 1997.
22. Ugozzoli, M., O'Hagan, D.T., and Ott, G.S. Intranasal Immunization of Mice with Herpes Simplex Virus (HSV) Type II Recombinant gD2: The Effect of Adjuvants on Mucosal and Serum Antibody Responses. *Immunol.* 3(4): 563, 1998
23. Barackman, J.D., Singh, M., Ugozzoli, M., Ott, G.S., and O'Hagan, D.T. Oral Immunization with poly (lactide-co-glycolide) Microparticles Containing an Entrapped Recombinant Glycoprotein (gD2) from Herpes Simplex Type 2 Virus, *STP Pharma. Sci.* 8(1): 41 1998
24. Dupuis, M., Murphy, T.J., Higgins, D., Ott, G., Van Nest, G., and McDonald, D. Dendritic Cells Internalize Vaccine Adjuvant after Intramuscular Injection. *Cell Immunol.* 186(1): 18. 1998
25. Singh, M., Carlson, J.R., Briones, M., Ugozzoli, M., Kazzaz, J., Barackman, J., Ott, G. and O'Hagan, D.T. A comparison of biodegradable particles and MF59 as systemic adjuvants for recombinant gD2 from HSV-2, *Vaccine* 16(19):1822 1998



26. O'Hagan, D.T., Goldbeck, C., Ugozzoli, M., Ott, G., and Burke, R.L., Intranasal immunization with recombinant gD2 reduces disease severity and morbidity following genital challenge with herpes simplex virus type 2 in guinea pigs, *Vaccine* 17(18): 2229 1999
27. Barackman, J.D., Ott, G. and O'Hagan, D.T. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization, *Infect Immun* 67(8): 4276 1999
28. Dupuis, M., McDonald, D.M. and Ott, G., Distribution of the adjuvant MF59 and antigen gD2 after intramuscular injection in mice, *Vaccine*, 18(5-6): 434 1999
29. O'Hagan, D.T., Ugozzoli, M., Barackman, J., Singh, M., Kazzaz, J., Higgins, K., VanCott, T.C. and Ott, G. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1, *Vaccine* 18(17) 1793-1801 2000
30. Kazzaz, J., Neidleman, J., Singh, M., Ott, G. and O'Hagan, D.T., Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1 *J Controlled Release* in press
31. Singh, M., Briones, M., Ott, G. and O'Hagan, D. Cationic Microparticles: A potent delivery system for DNA Vaccines, *PNAS* 97(2) 811-816 2000
32. Ott, G. Radhakrishnan, R., Fang, J., and Hora, M., The Adjuvant MF59: The 10 Year Perspective *Methods in Molecular Medicine* V42 (ed. D.T. O'Hagan) Humana Press Totowa NJ 211-228 2000
32. Dupuis, M., Denis-Mize, K., Woo, C., Goldbeck, C., Selby, M., Chen, M., Otten, G., Ulmer, J., Donnelly, J., Ott, G. and McDonald, D., Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. (submitted for publication)
33. Denis-Mize, K., Dupuis, M., MacKichan, M., Donnelly, J., McDonald, D. and Ott, G., Plasmid DNA formulated on PLG-CTAB microparticles mediates target gene expression and antigen presentation by dendritic cells. (submitted for publication)

**w/o  
emulsion**




FIG. 1B

**o/w  
emulsion**




FIG. 1A